FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366393754> ?p ?o ?g. }

• W4366393754 endingPage "659" @default.
• W4366393754 startingPage "643" @default.
• W4366393754 abstract "To compare adherence to once-daily umeclidinium/vilanterol (UMEC/VI), a long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA), and twice-daily inhaled corticosteroids (ICS)/LABA single-inhaler dual therapy in patients with chronic obstructive pulmonary disease (COPD) in a primary care cohort in England.Active comparator, new-user, retrospective cohort study using CPRD-Aurum primary care data and linked Hospital Episode Statistics secondary care administrative data. Patients without exacerbations in the previous year were indexed on first/earliest prescription date of once-daily UMEC/VI or twice-daily ICS/LABA as initial maintenance therapy between July 2014-September 2019. Primary outcome: medication adherence at 12 months post-index, defined as proportion of days covered (PDC) ≥80%. PDC represented proportion of time over the treatment duration that the patient was theoretically in possession of the medication. Secondary outcomes: adherence at 6, 18, and 24 months post-index, time-to-triple therapy, time-to-first on-treatment COPD exacerbation, COPD-related and all-cause healthcare resource utilization (HCRU), and direct health-care costs. A propensity score was generated and inverse probability of treatment weighting (IPTW) was used to balance potential confounders. Superiority was defined as >0% difference between treatment groups.In total, 6815 eligible patients were included (UMEC/VI:1623; ICS/LABA:5192). At 12 months post-index, weighted odds of a patient being adherent were significantly greater with UMEC/VI versus ICS/LABA (odds ratio [95% CI]: 1.71 [1.09, 2.66]; p=0.0185), demonstrating superiority of UMEC/VI. Patients taking UMEC/VI were statistically significantly more adherent than those taking ICS/LABA at 6, 18, and 24 months post-index (p<0.05). Differences in time-to-triple therapy, time-to-moderate COPD exacerbations, HCRU, and direct medical costs were not statistically significant between treatments after IPTW was applied.At 12 months post-treatment initiation, once-daily UMEC/VI was superior to twice-daily ICS/LABA in medication adherence among patients with COPD without exacerbations in the previous year, newly initiating dual maintenance therapy in England. The finding was consistent at 6, 18, and 24 months." @default.
• W4366393754 created "2023-04-21" @default.
• W4366393754 creator A5001030412 @default.
• W4366393754 creator A5002252420 @default.
• W4366393754 creator A5008821406 @default.
• W4366393754 creator A5014641457 @default.
• W4366393754 creator A5020186225 @default.
• W4366393754 creator A5034800401 @default.
• W4366393754 creator A5042278243 @default.
• W4366393754 creator A5044010239 @default.
• W4366393754 creator A5046338978 @default.
• W4366393754 creator A5067651492 @default.
• W4366393754 creator A5070785494 @default.
• W4366393754 creator A5071404281 @default.
• W4366393754 creator A5087678558 @default.
• W4366393754 date "2023-04-01" @default.
• W4366393754 modified "2023-09-26" @default.
• W4366393754 title "Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England" @default.
• W4366393754 cites W2039206076 @default.
• W4366393754 cites W2053237747 @default.
• W4366393754 cites W2095666112 @default.
• W4366393754 cites W2105597522 @default.
• W4366393754 cites W2113033841 @default.
• W4366393754 cites W2138833643 @default.
• W4366393754 cites W2152590022 @default.
• W4366393754 cites W2153810843 @default.
• W4366393754 cites W2172005465 @default.
• W4366393754 cites W2295597785 @default.
• W4366393754 cites W2365138737 @default.
• W4366393754 cites W2554373806 @default.
• W4366393754 cites W2596492194 @default.
• W4366393754 cites W2607275024 @default.
• W4366393754 cites W2608320814 @default.
• W4366393754 cites W2610869540 @default.
• W4366393754 cites W2613601294 @default.
• W4366393754 cites W2621103729 @default.
• W4366393754 cites W2744579741 @default.
• W4366393754 cites W2746562707 @default.
• W4366393754 cites W2911336697 @default.
• W4366393754 cites W2965866848 @default.
• W4366393754 cites W2992852262 @default.
• W4366393754 cites W3084659043 @default.
• W4366393754 cites W3149026346 @default.
• W4366393754 cites W3156817660 @default.
• W4366393754 cites W3200236352 @default.
• W4366393754 cites W3205211596 @default.
• W4366393754 doi "https://doi.org/10.2147/copd.s405498" @default.
• W4366393754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37155496" @default.
• W4366393754 hasPublicationYear "2023" @default.
• W4366393754 type Work @default.
• W4366393754 citedByCount "0" @default.
• W4366393754 crossrefType "journal-article" @default.
• W4366393754 hasAuthorship W4366393754A5001030412 @default.
• W4366393754 hasAuthorship W4366393754A5002252420 @default.
• W4366393754 hasAuthorship W4366393754A5008821406 @default.
• W4366393754 hasAuthorship W4366393754A5014641457 @default.
• W4366393754 hasAuthorship W4366393754A5020186225 @default.
• W4366393754 hasAuthorship W4366393754A5034800401 @default.
• W4366393754 hasAuthorship W4366393754A5042278243 @default.
• W4366393754 hasAuthorship W4366393754A5044010239 @default.
• W4366393754 hasAuthorship W4366393754A5046338978 @default.
• W4366393754 hasAuthorship W4366393754A5067651492 @default.
• W4366393754 hasAuthorship W4366393754A5070785494 @default.
• W4366393754 hasAuthorship W4366393754A5071404281 @default.
• W4366393754 hasAuthorship W4366393754A5087678558 @default.
• W4366393754 hasBestOaLocation W43663937541 @default.
• W4366393754 hasConcept C126322002 @default.
• W4366393754 hasConcept C156957248 @default.
• W4366393754 hasConcept C1862650 @default.
• W4366393754 hasConcept C2776780178 @default.
• W4366393754 hasConcept C2776804153 @default.
• W4366393754 hasConcept C2777014857 @default.
• W4366393754 hasConcept C2779028295 @default.
• W4366393754 hasConcept C2780911369 @default.
• W4366393754 hasConcept C71924100 @default.
• W4366393754 hasConcept C72563966 @default.
• W4366393754 hasConceptScore W4366393754C126322002 @default.
• W4366393754 hasConceptScore W4366393754C156957248 @default.
• W4366393754 hasConceptScore W4366393754C1862650 @default.
• W4366393754 hasConceptScore W4366393754C2776780178 @default.
• W4366393754 hasConceptScore W4366393754C2776804153 @default.
• W4366393754 hasConceptScore W4366393754C2777014857 @default.
• W4366393754 hasConceptScore W4366393754C2779028295 @default.
• W4366393754 hasConceptScore W4366393754C2780911369 @default.
• W4366393754 hasConceptScore W4366393754C71924100 @default.
• W4366393754 hasConceptScore W4366393754C72563966 @default.
• W4366393754 hasLocation W43663937541 @default.
• W4366393754 hasLocation W43663937542 @default.
• W4366393754 hasLocation W43663937543 @default.
• W4366393754 hasOpenAccess W4366393754 @default.
• W4366393754 hasPrimaryLocation W43663937541 @default.
• W4366393754 hasRelatedWork W2098395208 @default.
• W4366393754 hasRelatedWork W2355556544 @default.
• W4366393754 hasRelatedWork W2554469774 @default.
• W4366393754 hasRelatedWork W2554954966 @default.
• W4366393754 hasRelatedWork W2570676203 @default.
• W4366393754 hasRelatedWork W2802779683 @default.
• W4366393754 hasRelatedWork W2897168099 @default.

• next